SynthesisScientific reports2021

Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20

Chengxin Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.